fondaparinux sodium

ApprovedSmall molecule

fondaparinux sodium is a small molecule that works as Antithrombin-III Activator.[2] It is being used across 15 indications, with its most advanced program in Approved.[1]

fondaparinux sodium is one of 310 small molecule programs targeting Thrombophlebitis. It is currently in Approved.

Indications

Total Trials

Active Trials

309

Competitors

Pipeline

Status by Indication[3][1]

Indication

ThrombophlebitisActive, not recruiting

Total Joint ArthroplastyActive, not recruiting

Cardiovascular DiseaseActive, not recruiting

Intermediate Coronary SyndromeUnknown

Venous ThromboembolismUnknown

Venous ThrombosisUnknown

HemorrhageActive, not recruiting

Myocardial InfarctionUnknown

ThromboembolismActive, not recruiting

Deep Vein ThrombosisUnknown

ThrombophlebitisApproved

Active, not recruiting

Total Joint ArthroplastyApproved

Active, not recruiting

Cardiovascular DiseasePreclinical

Active, not recruiting

Intermediate Coronary SyndromePreclinical

Unknown

Venous ThromboembolismPreclinical

Unknown

Venous ThrombosisPreclinical

Unknown

HemorrhagePreclinical

Active, not recruiting

Myocardial InfarctionPreclinical

Unknown

ThromboembolismPhase 3

Active, not recruiting

Deep Vein ThrombosisPreclinical

Unknown

Showing 10 of 15 indications

Competition

Competitive Landscape

274 competitors in Cardiovascular Disease

#DrugCompanyPhaseTrials

fondaparinux sodium

GSK

Approved

19 2

Dalcetrapib

Roche

Phase 3

1 3

Ziltivekimab

Novo Nordisk

Phase 3

1 4

Obicetrapib

NNewAmsterdam Pharma

Phase 3

1 5

Repatha

Amgen

Preclinical

5 6

Mounjaro

Eli Lilly

Preclinical

1 7

Praluent

Regeneron

Preclinical

1 8

Calciferol

Alnylam Pharmaceuticals

Preclinical

1 9

Myrbetriq

Astellas

Preclinical

1 10

Benicar

Novartis

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2029

Post-ApprovalRecruiting

Myocardial Infarction

NCT06710184

Clinical

Trials by Indication[1]

Thromboembolism2 trials

The Use of Fondaparinux in Preventing Thromboembolism in High Risk Trauma Patients

Completed·MMary Knudson, M.D.·Phase 2/3·NCT00531843·105 enrolled

The Treatment of Acute Pulmonary Thromboembolism (PE) of GSK576428 (Fondaparinux Sodium) in Japanese Patients

Completed· GSK logo

GSK·Phase 3·NCT00981409·41 enrolled

Venous Thromboembolism2 trials

Special Drug Use Investigation for Arixtra® (Fondaparinux) Venous Thromboembolism Treatment

Completed· GSK logo

GSK··NCT01428531·200 enrolled

Special Drug Use Investigation (Retrospective) for Arixtra® (Fondaparinux) Venous Thromboembolism Treatment (Over 100kg)

Completed· GSK logo

GSK··NCT01428544·5 enrolled

Percutaneous Coronary Intervention (PCI)1 trial

A Safety and Efficacy Trial Evaluating the Use of Fondaparinux in Percutaneous Coronary Intervention (PCI)(63133)(WITHDRAWN)

Withdrawn·SSchering-Plough·Phase 2·NCT00060554·300 enrolled

Kidney Failure1 trial

Fondaparinux as an Anticoagulant in Haemofiltration in Patients With Acute Kidney Failure.

Terminated·MMelbourne Health·N/A·NCT00256100·20 enrolled

Myocardial Infarction1 trial

Treatment With Aspirin Alone Versus Aspirin in Combination With Fondaparinux Before Early Coronary Assessment in Patients With Non-ST-Elevation Myocardial Infarction

Recruiting·UUniversity of Aarhus·Phase 4·NCT06710184·5,076 enrolled

12 more indications

Gynecologic Cancer1 trial

Fondaparinux in Preventing Blood Clots in Patients Undergoing Surgery for Gynecologic Cancer

Completed·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT00381888·44 enrolled

Major Abdominal Surgery1 trial

A Study to Evaluate the Efficacy and Safety of Fondaparinux Sodium When Used With Intermittent Pneumatic Compression to Prevent Venous Thromboembolic (IPC) Versus IPC Alone for the Prevention of Venous Thromboembolic Events in Subjects at Increased Risk Undergoing Major Abdominal Surgery (APOLLO).

Completed· GSK logo

GSK·Phase 3·NCT00038961·1,309 enrolled

Hemorrhage1 trial

Hemorrhage Risk Prescribed Arixtra

Completed· GSK logo

GSK··NCT01064362·13,442 enrolled

Deep Vein Thrombosis1 trial

The Treatment of Acute Deep Vein Thrombosis (DVT) of GSK576428 (Fondaparinux Sodium) in Japanese Patients

Completed· GSK logo

GSK·Phase 3·NCT00911157·39 enrolled

Total Joint Arthroplasty1 trial

The Effects of Arixtra on Wound Drainage Following Total Joint Arthroplasty

Completed·PPaul Di Cesare,MD·Phase 4·NCT00909064·114 enrolled

Function1 trial

"Pharmacokinetic Study of Fondaparinux in Inpatients With Renal Dysfunction"

Completed·—·Phase 1·NCT01121770·9 enrolled

Knee Injury1 trial

A Study to Evaluate the Efficacy and Safety of Fondaparinux for the Prevention of Venous Blood Clots in Patients With a Plaster Cast or Other Type of Immobilization for a Below-knee Injury Not Needing Surgery

Completed· GSK logo

GSK·Phase 3·NCT00843492·1,351 enrolled

Drug1 trial

Special Drug Use Investigation for ARIXTRA (Fondaparinux) Abdominal (Urology,Obstetrics,Gynecology)

Completed· GSK logo

GSK··NCT01390883·475 enrolled

Medication1 trial

Investigation Into the Therapeutic Dosage of Fondaparinux Sodium, a Medication Used to Prevent Blood Clots in Morbidly Obese Volunteers

Completed·UUniversity of Pittsburgh·Phase 2·NCT00436787·21 enrolled

General Surgery1 trial

Special Drug Use Investigation for ARIXTRA (Fondaparinux) Abdominal General Surgery

Completed· GSK logo

GSK··NCT01390896·329 enrolled

Abdominal Surgery1 trial

Abdominal Surgery Study Of GSK576428 (Fondaparinux Sodium)In Japanese Patients

Completed· GSK logo

GSK·Phase 3·NCT00333021·127 enrolled

Thrombophlebitis1 trial

Endovenous Laser Ablation in Acute Thrombophlebitis of the Varicose Great Saphenous Vein

Completed·UUnknown Sponsor·Phase 4·NCT05001776·105 enrolled

Sources

References

[1]
ClinicalTrials.gov — 19 trial records for fondaparinux sodium. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — fondaparinux sodium compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for fondaparinux sodium. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — GSK company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Antithrombin-III Activator[2]
Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: GSK

fondaparinux sodium

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2029

Trials by Indication[1]

Thromboembolism2 trials

Venous Thromboembolism2 trials

Percutaneous Coronary Intervention (PCI)1 trial

Kidney Failure1 trial

Myocardial Infarction1 trial

Gynecologic Cancer1 trial

Major Abdominal Surgery1 trial

Hemorrhage1 trial

Deep Vein Thrombosis1 trial

Total Joint Arthroplasty1 trial

Function1 trial

Knee Injury1 trial

Drug1 trial

Medication1 trial

General Surgery1 trial

Abdominal Surgery1 trial

Thrombophlebitis1 trial

References

Drug Info

Quick Facts

Related News